stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Gross margin
Xenon Pharmaceuticals Inc.'s gross margin over the twelve months to 31 March 2025 was 28.4%. Over the past ten years it has ranged from 0.00% (fiscal 2018) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 100.0% | 0.00 |
| FY2022 | 100.0% | 0.00 |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 100.00 |
| FY2018 | 0.00% | (100.00) |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | 0.00 |
| FY2015 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Mar 2025 | 100.0% | 100.00 |
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| 26 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| ABCL AbCellera Biologics Inc. compare | 100.0% |
| TNGX Tango Therapeutics, Inc. compare | 100.0% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 90.5% |
| XENE Xenon Pharmaceuticals Inc. | 28.4% |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement